Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

JAZZ Relative to the S&P 500

JAZZ Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Jazz Pharmaceuticals, Inc. (NASD:JAZZ) seasonal charts above shows that a Buy Date of May 31 and a Sell Date of August 19 has resulted in a geometric average return of 13.53% above the benchmark rate of the S&P 500 Total Return Index over the past 18 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 18 years by an average of 10.31% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

To download JAZZ seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: JAZZ